Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications CNS cancer; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Papilloma
- Focus Therapeutic Use
- 14 Jan 2025 Planned End Date changed from 21 Apr 2027 to 15 Jul 2026.
- 14 Jan 2025 Planned primary completion date changed from 21 Apr 2026 to 15 Jul 2025.
- 14 Jan 2025 Status changed from recruiting to active, no longer recruiting.